

Freedom of Information Request	FOI 21-346	7 <sup>th</sup> September 2021
--------------------------------	------------	--------------------------------

**a. How many patients has your trust treated in the last 12 months with the following drugs?**

The Health Board is unable to supply data on how many patients have been treated. However, we have supplied quantities dispensed from our pharmacy departments for the period September 2020 – August 2021:

- **Genotropin**
- **Humatrope**
- **Norditropin**
- **Nutropin**
- **Omnitrope**
- **Saizen**
- **Zomacton**
- **Any other Somatropin (please specify)**  
Somatropin Prefilled 0.2mg (0.6 unit) 1 pre filled syringe x 7  
Somatropin 6mg (18 units) injection cartridge x 1

**b. Please provide the number of patients under the age of 16 that were treated in the last 12 months with each of the following drugs:**

- **Genotropin**
- **Humatrope**
- **Norditropin**
- **Nutropin**
- **Omnitrope**
- **Saizen**
- **Zomacton**
- **Any other Somatropin (please specify)**

The Health Board does not record this information centrally. In order to determine this, the Health Board would have to review every patient record. Therefore in order to comply with your request the Health Board has established that this would exceed the appropriate costs limit under Section 12 of the Freedom of Information Act 2000 which is currently £450. As you will be aware this is not an exemption which requires us to consider the application of the public interest test. We have calculated that it would take in excess of 18 hours to review the record of each patient.

**c. Within your trust, how many patients have been diagnosed (primary or secondary diagnosis) in the past 12 months for the following conditions:**

The Health Board is only able to provide data for patients who have been treated/admitted as either an inpatient or a day case during this period.

- **Neuromuscular dysfunction of bladder (ICD-10 Code N31.9)**

During the 12 month period from July 2020 to June 2021, 33 patients with a diagnosis of neuromuscular dysfunction of the bladder (N31.9) were coded

- **Cervical dystonia (ICD-10 code G24.3)**

During the 12 month period from July 2020 to June 2021, less than 5 patients with a diagnosis of cervical dystonia (G24.3) were coded.

Please note that Section 40 of the Freedom of Information Act 2000 has been applied. The Health Board will not provide the exact numbers due to the low numbers of individuals involved (5 or less). The Health Board believes there is a potential risk of individuals being able to be identified, when considered with other information already available within the public domain, if this was disclosed. Therefore, the data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.

**d. For patients diagnosed with neuromuscular dysfunction of bladder as per question c above, how many patients have been treated in the last 3 months with the following products:**

- **Botox**
- **Dysport**
- **Xeomin**

The Health Board is unable to supply data on how many patients have been diagnosed with a particular illness. However, we have supplied quantities dispensed from our pharmacy departments for the period June 2021 – August 2021

Botulinum Toxin Type A (BOTOX) 100 units injection 1 vial pack = 90  
Botulinum Toxin Type A (BOTOX) 200 units injection 1 vial pack = 85  
Botulinum Toxin Type A (BOTOX) 50 units injection 1 vial pack = 27  
Botulinum Toxin Type A (BOTOX) 300units injection 1 vial pack = 15  
Botulinum Toxin Type A (DYSPORT) 500 units injection 2 vial pack = 18  
Botulinum Toxin Type A (XEOMIN) 100 units injection 1 vial pack = 5  
Botulinum Toxin Type A (XEOMIN) 200 units Injection 1 vial pack = 9  
Botulinum Toxin Type A (XEOMIN) 50 units injection 1 vial pack = 25

**e. For patients diagnosed with cervical dystonia as per question c above, how many patients have been treated in the last 3 months with the following products:**

- **Botox**
- **Dysport**
- **Xeomin**

Please refer to Question d.